{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:58:56Z","timestamp":1785560336887,"version":"3.56.0"},"reference-count":36,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5582\/bst.2026.01077","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:10:17Z","timestamp":1785449417000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological characterization and prognostic factors of H3 K27M-altered diffuse midline gliomas: A real-world cohort study"],"prefix":"10.5582","author":[{"given":"Chunbo","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwu","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"Clinical Research Center for Skull Base Surgery and Neuro-oncology in Hunan Province, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China."},{"name":"Department of Neurosurgery, The Second People&apos;s Hospital of Hainan Province, Wuzhishan, Hainan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fushu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongye","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"Clinical Research Center for Skull Base Surgery and Neuro-oncology in Hunan Province, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"Clinical Research Center for Skull Base Surgery and Neuro-oncology in Hunan Province, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Meel MH, Kaspers GJL, Hulleman E. Preclinical therapeutic targets in diffuse midline glioma. Drug Resist Updat. 2019; 44:15-25.","DOI":"10.1016\/j.drup.2019.06.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23:1231-1251.","DOI":"10.1093\/neuonc\/noab106"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, <i>et al<\/i>. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018; 36:1963- 1972.","DOI":"10.1200\/JCO.2017.75.9308"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020; 19:776-800.","DOI":"10.1038\/s41573-020-0077-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Marqu\u00e9s M, Real FX. PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets. Eur Urol. 2017; 71:863-865.","DOI":"10.1016\/j.eururo.2017.01.049"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Song G, Liu J, Tang X, Zhong J, Zeng Y, Zhang X, Zhou J, Zhou J, Cao L, Zhang Q, Li Y. Cell cycle checkpoint revolution: targeted therapies in the fight against malignant tumors. Front Pharmacol. 2024; 15:1459057.","DOI":"10.3389\/fphar.2024.1459057"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Drew Y, Zenke FT, Curtin NJ. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat Rev Drug Discov. 2025; 24:19-39.","DOI":"10.1038\/s41573-024-01060-w"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J. PARP inhibition promotes ferroptosis <i>via<\/i> repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021; 42:101928.","DOI":"10.1016\/j.redox.2021.101928"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett. 2020; 490:174-185.","DOI":"10.1016\/j.canlet.2020.07.022"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, O&apos;Neill N; PROCESS Group. The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasESeries in Surgery (PROCESS) Guidelines. Int J Surg. 2020; 84:231-235.","DOI":"10.1016\/j.ijsu.2020.11.005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wu C, Gong S, Duan Y, Deng C, Kallendrusch S, Berninghausen L, Osterhoff G, Schopow N. A tumor microenvironment-based prognostic index for osteosarcoma. J Biomed Sci. 2023; 30:23.","DOI":"10.1186\/s12929-023-00917-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wu C, Su J, Wang X, Wang J, Xiao K, Li Y, Xiao Q, Ling M, Xiao Y, Qin C, Long W, Zhang F, Pan Y, Xiang F, Liu Q. Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis. Cancer Manag Res. 2019; 11:3139-3152.","DOI":"10.2147\/CMAR.S199207"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Liu Y, Ma J, Wang X, Liu P, Cai C, Han Y, Zeng S, Feng Z, Shen H. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma. Comput Biol Med. 2023; 158:106862.","DOI":"10.1016\/j.compbiomed.2023.106862"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. van den Bent MJ, Tesileanu CMS, Wick W, <i>et al<\/i>. Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021; 22:813-823.","DOI":"10.1016\/S1470-2045(21)00090-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007; 7:16.","DOI":"10.1186\/1472-6947-7-16"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zheng L, Gong J, Yu T, Zou Y, Zhang M, Nie L, Chen X, Yue Q, Liu Y, Mao Q, Zhou Q, Chen N. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases. Am J Surg Pathol. 2022; 46:863-871.","DOI":"10.1097\/PAS.0000000000001897"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Travaglino A, Raffone A, Catena U, De Luca M, Toscano P, Del Prete E, Vecchione ML, Lionetti R, Zullo F, Insabato L. Ki67 as a prognostic marker in uterine leiomyosarcoma: A quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2021; 266:119-124.","DOI":"10.1016\/j.ejogrb.2021.09.026"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129:829-848.","DOI":"10.1007\/s00401-015-1432-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gong X, Kuang S, Deng D, Wu J, Zhang L, Liu C. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma. CNS Neurosci Ther. 2023; 29:3863-3875.","DOI":"10.1111\/cns.14307"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hoogendijk R, van der Lugt J, Kranendonk MEG, Gatta G, Capocaccia R, Hoving EW, Wesseling P, Visser O, van Vuurden DG, Karim-Kos H. Protocol for investigating data quality and reporting outcomes of pediatric gliomas in population-based cancer registry research. STAR Protoc. 2024; 5:102905.","DOI":"10.1016\/j.xpro.2024.102905"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Radkiewicz C, Johansson ALV, Dickman PW, Lambe M, Edgren G. Sex differences in cancer risk and survival: A Swedish cohort study. Eur J Cancer. 2017; 84:130-140.","DOI":"10.1016\/j.ejca.2017.07.013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011; 20:1629-1637.","DOI":"10.1158\/1055-9965.EPI-11-0246"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tewari S, Tom MC, Park DYJ, <i>et al<\/i>. Sex-Specific Differences in Low-Grade Glioma Presentation and Outcome. International journal of radiation oncology, biology, physics. 2022; 114:283-292.","DOI":"10.1016\/j.ijrobp.2022.05.036"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ostrom QT, Kinnersley B, Wrensch MR, <i>et al<\/i>. Sex-Specific Differences in Low-Grade Glioma Presentation and Outcome. Int J Radiat Oncol Biol Phys. 2022; 114:283-292.","DOI":"10.1016\/j.ijrobp.2022.05.036"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jalali A, Yu K, Beechar V, Bosquez Huerta NA, Grichuk A, Mehra D, Lozzi B, Kong K, Scott KL, Rao G, Bainbridge MN, Bondy ML, Deneen B. POT1 Regulates Proliferation and Confers Sexual Dimorphism in Glioma. Cancer Res. 2021; 81:2703-2713.","DOI":"10.1158\/0008-5472.CAN-20-3755"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Erker C, Lane A, Chaney B, <i>et al<\/i>. Characteristics of patients \u226510 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG\/DMG Registry. Neuro Oncol. 2022; 24:141-152.","DOI":"10.1093\/neuonc\/noab140"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cacciotti C, Wright KD. Advances in Treatment of Diffuse Midline Gliomas. Curr Neurol Neurosci Rep. 2023; 23:849-856.","DOI":"10.1007\/s11910-023-01317-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011; 13:298-306.","DOI":"10.1093\/neuonc\/noq202"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Di Nunno V, Lombardi G, Simonelli M, <i>et al<\/i>. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study. J Neurooncol. 2024; 167:145-154.","DOI":"10.1007\/s11060-024-04589-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Duchatel RJ, Jackson ER, Parackal SG, <i>et al<\/i>. PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma. J Clin Invest. 2024; 134:e170329.","DOI":"10.1172\/JCI170329"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Dunkel IJ, Doz F, Foreman NK, <i>et al<\/i>. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023; 25:1530-1545.","DOI":"10.1093\/neuonc\/noad031"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Vitanza NA, Wilson AL, Huang W, <i>et al<\/i>. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov. 2023; 13:114-131.","DOI":"10.1093\/neuonc\/noad073.315"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Majzner RG, Ramakrishna S, Yeom KW, <i>et al<\/i>. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022; 603:934-941.","DOI":"10.1038\/s41586-022-04489-4"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ronsley R, Bertrand KC, Song EZ, Timpanaro A, Choe M, Tlais D, Vitanza NA, Park JR. CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials. Cancer Metastasis Rev. 2024; 43:1205-1216.","DOI":"10.1007\/s10555-024-10208-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. G\u00e1llego P\u00e9rez-Larraya J, Garcia-Moure M, Labiano S, <i>et al<\/i>. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med. 2022; 386:2471-2481.","DOI":"10.1056\/NEJMoa2202028"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. de la Nava D, Ausejo-Mauleon I, Laspidea V, <i>et al<\/i>. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol. 2024; 26:1509-1525.","DOI":"10.1093\/neuonc\/noae066"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/advpub\/0\/advpub_2026.01077\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:29:04Z","timestamp":1785558544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/advpub\/0\/advpub_2026.01077\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01077","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.01077"}}